American journal of blood research最新文献

{"title":"Diagnostic accuracy of reticulocyte parameters on the sysmex XN 1000 for discriminating iron deficiency anaemia and thalassaemia in Saudi Arabia.","authors":"Qanita Sedick,&nbsp;Ghaleb Elyamany,&nbsp;Huda Hawsawi,&nbsp;Sultan Alotaibi,&nbsp;Fahad Alabbas,&nbsp;Mohammed Almohammadi,&nbsp;Hassan A Alahmari,&nbsp;Hassan Aljasem,&nbsp;Arnel G Ferrer,&nbsp;Ahmed S Alzahrani,&nbsp;May AlMoshary,&nbsp;Omar Alsuhaibani","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Iron deficient erythropoiesis and Thalassaemia are both associated with microcytic erythropoiesis albeit from different pathological mechanisms. Given the high prevalence of Hemoglobinopathies in the Mediterranean region, discriminating these two conditions is important. Several algorithms using conventional red cell indices have been developed to facilitate diagnosis, however, their diagnostic accuracy is low. The new generation haematology analyzers enabled the use of more innovative parameters such as reticulocyte parameters. We aimed to evaluate the diagnostic performance of the reticulocyte parameters on the Sysmex XN 1000 to distinguish between IDA and Thalassemia in our population.</p><p><strong>Methods: </strong>We performed a retrospective analysis of blood samples sent to our laboratory for haemoglobin electrophoresis screening. We categorized our cohort into Thalassemia and Iron Deficient patients based on known diagnostic criteria. We analyzed the reticulocyte parameters using receiver operator curve analysis (ROC) and determined the cut off value for each parameter.</p><p><strong>Results: </strong>Reticulocyte parameters most accurate for discriminating IDA from Thalassemia patients was: RET, RET-HE and IRF. The RET-HE had the best statistical significance for IDA patients with AUC = 0.69 for cut off 22.25. The RET-HE for dual positive patients was more accurate with AUC = 0.78 for cut off 21.25. The IRF had the best statistical significance for Alpha Thalassemia with AUC = 0.66 for cut off value 18.</p><p><strong>Conclusion: </strong>An IRF cut off below 15.5 and RET-HE cut off below 22.25 was the most accurate variable in predicting IDA with a sensitivity of 59.4% and 68.3%.</p>","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 2","pages":"172-179"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165718/pdf/ajbr0011-0172.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38986753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital acquired infection in a department of hematology-oncology care in the Congo.","authors":"Lydie Ocini Ngolet,&nbsp;Alexis Fortuné Bolenga Liboko,&nbsp;Bienvenu Roland Ossibi Ibara,&nbsp;Alexis Elira Dokekias","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Hospital Acquired Infection (HAI) is a major cause of morbidity and mortality in hemato-oncology. The study aims to report the incidence of hospital-acquired infections in patients with hematological malignancies and the risk factors associated with them.</p><p><strong>Material and methods: </strong>An observational study with cross-sectional data collection was carried out from January 1, 2019, to April 30, 2020, in the department of hematology of Brazzaville University Hospital. The study concerned 77 patients diagnosed with hematological malignancies admitted for a course of chemotherapy. Written consent was obtained from each participant. Participants were divided into two groups: with HAI (n=50) and without HAI (n=27). They were compared using the chi-square test and Student's T-test. Univariate and multivariate analyses of the association of HAI with all the risk factors were performed for analysis of the 2 x k contingency tables and repeated using logistic regression.</p><p><strong>Results: </strong>The cumulative incidence was 64.9% with a 95% confidence interval of [53.8-74.7]. The time to onset of HAIs was 10.6±6.50 days. The incidence of HAI was significantly greater in acute myelogenous leukemia (80%), grade 4 neutropenia (80%). The risk factors were hospitalization stay of over 14 days (OR: 1.09), the regimen: daunorubicin-aracytine (OR: 5.96), the hemoglobin level on admission (OR: 0.72), and the neutropenia of grade 4 (OR: 7.9). The most common clinically identified focus of infection was peripheral venous infections. The fatality rate was 10%.</p><p><strong>Conclusion: </strong>The determination of HAI and the identification of its risk factors make it possible to establish prevention strategies.</p>","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 2","pages":"191-198"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165720/pdf/ajbr0011-0191.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38986755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower hair cortisol among patients with sickle cell disease may indicate decreased adrenal reserves.","authors":"Brittany M Hollister,&nbsp;Mihail Zilbermint,&nbsp;Caterina P Minniti,&nbsp;Ashley J Buscetta,&nbsp;Khadijah E Abdallah,&nbsp;Shuo You,&nbsp;Steven J Soldin,&nbsp;Jerrold S Meyer,&nbsp;Constantine A Stratakis,&nbsp;Vence L Bonham","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Sickle cell disease (SCD) is a chronic illness that presents with a wide range of phenotypic variation. Stress may be a contributing factor to differences that are found in this population.</p><p><strong>Objectives: </strong>Our objective is to determine the relationship between hair cortisol content (HCC), a biomarker of stress, and other clinical measures in individuals with SCD.</p><p><strong>Methods: </strong>We collected hair samples and other clinical measures from 73 subjects with SCD (mean age: 39 ± 12 years, 63% female).</p><p><strong>Results: </strong>HCC was lower among individuals who had greater than 30% hemoglobin S, compared with those who had less than 30% hemoglobin S (W=272.5, P=0.01). Lower HCC was also associated with report of not being on a chronic transfusion program (β=48.34, SE=14.09, P=0.001) and higher ferritin levels (β=-0.006, SE=0.002, P=0.02). Furthermore, HCC was significantly correlated with serum cortisol (r_s=0.26, P=0.03) and corticosterone (r_s=0.29, P=0.01). We also observed a consistent pattern of low steroid values among our population.</p><p><strong>Conclusion: </strong>Our findings suggest that individuals with higher hemoglobin S and ferritin, both markers of severe SCD, may have decreased cortisol levels. This is consistent with the relationship we observed between higher HCC among individuals who are on a chronic blood transfusion program, which typically increases quality of life. Our results suggest that hair cortisol may be an indicator in patients with SCD who could be at risk for developing adrenal insufficiency. We recommend that clinicians treating patients with SCD follow the Endocrine Society guidelines for testing for adrenal insufficiency and treat accordingly.</p>","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 2","pages":"140-148"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165714/pdf/ajbr0011-0140.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38986748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eltrombopag post autologous hematopoietic stem cell transplant - an emerging indication in younger pediatric patients.","authors":"Aditya Kumar Gupta,&nbsp;Prasanth Srinivasan,&nbsp;Gargi Das,&nbsp;Jagdish Prasad Meena,&nbsp;Pranay Tanwar,&nbsp;Rachna Seth","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Engraftment of neutrophils and platelets after hematopoietic stem cell transplant (HSCT) is imperative for optimal outcomes. Eltrombopag has been used in adults after HSCT to boost platelet production. Its use in pediatric post HSCT patients has been limited.</p><p><strong>Methods: </strong>The clinical and laboratory details of a post autologous HSCT patient were fetched by a retrospective review of the records.</p><p><strong>Results: </strong>A 5-year old male child had primary thrombocytopenia post autologous HSCT for refractory Hodgkin lymphoma. Although the stem cell dose infused was adequate, the child had a delay in the engraftment of platelets. After ruling out the causes of post HSCT thrombocytopenia, eltrombopag was started for the child. With the use of eltrombopag, normal thrombopoiesis was restored in the child.</p><p><strong>Conclusion: </strong>Eltrombopag was effective and safe in overcoming post-HSCT primary thrombocytopenia in our patient.</p>","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 2","pages":"168-171"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165717/pdf/ajbr0011-0168.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38986752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-globulin test positivity indicates advanced disease in Indian CLL patients.","authors":"Richa Gupta,&nbsp;Neha Garg,&nbsp;Abha Singh","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Autoimmune Hemolytic Anemia (AIHA) occurs in 10% to 25% of Chronic Lymphocytic Leukemia (CLL) while Direct Antiglobulin Test (DAT) positivity seen in 35% of cases. The prevalence and prognostic significance of DAT positivity is not well documented especially in Indian population. The present study was undertaken to know prevalence and prognostic significance of DAT positivity in CLL in India by associating it with stage and CD 38 expression. The study included fifty-eight newly diagnosed and untreated cases of CLL staged according to Binet and Rai system. Complete hemogram, DAT and immuno-phenotyping by flow cytometry was done to diagnose CLL and to assess CD 38 expression. Student's t test and Chi square test was used to calculate difference between means. <i>p</i> value ≤0.05 was considered significant. Results-DAT positivity was found in 27.58% cases. A positive association was seen between DAT and advanced Rai and Binet stage (P = 0.024 and P = 0.014 respectively). A positive association was also seen between DAT and CD 38 (P = 0.008). The study concluded that DAT positivity in Indian CLL patients is high as compared to West. As DAT correlated with advanced Rai/Binet stage, as well as CD 38 positivity, it can be considered as a surrogate marker for advanced disease and used to select patients needing close follow up especially at places where molecular and flow cytometric set up for prognostication is not available.</p>","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 2","pages":"157-162"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165719/pdf/ajbr0011-0157.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38986750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABO system combination with Rh, Kell and MN group in Georgian blood donors.","authors":"Marina Nagervadze,&nbsp;Irine Tsintsadze,&nbsp;Leila Akhvlediani,&nbsp;Tea Koiava,&nbsp;Sophiko Tskvitinidze,&nbsp;Rusudan Khukhunaishvili,&nbsp;Marina Koridze","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>There are numerous scientific data about the study of the prevalence of blood group antigens in the different donor population. Several studies showed that the profile of major blood group antigens is not similar in blood donors from different local areas.</p><p><strong>Research objective: </strong>Our scientific goal was to study of the prevalence blood group antigens in the Georgian blood donor population. In the current study, we analyzed the 48 phenotypically combinations based on four major (ABO, Rh, Kell, and MN) blood groups.</p><p><strong>Research methods: </strong>The blood of 1009 donors has been studied on RBC antigens. The sample were collected from the diagnostic laboratory of Medina Ltd Health Centre of Batumi. Blood typing of the sample has been carried out on the basis of the immunogenetics laboratory of Batumi Shota Rustaveli State University. The universal monoclone antibodies was used for identify minor blood group antigens. We used as forward as reverse grouping methods. For identification erythrocytes, blood group antigens also were used ID cards, such as ABO/D + Reverse Grouping.</p><p><strong>Result: </strong>12 phenotypic combinations have been identified in each O, A, B, AB group of ABO system. Out of 48 theoretically possible phenotypic combinations, we can actually find 1,9 times less phenotypes and the real amount is 25 phenotypes. The remaining 23 phenotypic combinations have not been observed in the studied donors. These are: 1. O, Rh^-K⁺ MM; 2. O, Rh^-K^- MN; 3. O, Rh^-K^- NN; 4. A, Rh^-K⁺ MN; 5. A, Rh^-K⁺ MM; 6. A, Rh^-K⁺ NN; 7. A, Rh^-K^- MM; 8. A, Rh^-K^- NN; 9. B, Rh⁺K⁺ NN; 10. B, Rh^-K⁺ MN; 11. B, Rh^-K⁺ MM; 12. B, Rh^-K⁺ NN; 13. B, Rh^-K^- MN; 14. B, Rh^-K^- MM; 15. B, Rh^-K^- NN; 16. AB, Rh⁺K⁺ MN; 17. AB, Rh⁺K⁺ NN; 18. AB, Rh⁺K^- NN; 19. AB, Rh⁺K^- MM; 20. AB, Rh^-K⁺ MN; 21. AB, Rh^-K⁺ MM; 22. AB, Rh^-K⁺ NN; 23. B, Rh^-K^- NN. The value of χ² in the case is equal to 3221,16. The <i>P</i>-Value is < .00001. The result is significant at P < .05. Out of 1009 studied donors 349 are carriers of phenotypic group A (II), while 19 donors carry AB (IV) group specification. This means that 36.23% of the studied donors have A antigen on the surface of erythrocyte membrane. The majority of them A1 subgroup.</p><p><strong>Conclusion: </strong>As our research showed there is a quit high polymorphism of blood group phenotype combinations in Georgian blood donors in the example of one clinic. This kind of data is very important for the cli","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 2","pages":"132-139"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165715/pdf/ajbr0011-0132.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38975420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Hematologic biomarkers and their combinations with disease severity and mortality in COVID-19- an Indian perspective.","authors":"Mukta Pujani,&nbsp;Sujata Raychaudhuri,&nbsp;Nikhil Verma,&nbsp;Harnam Kaur,&nbsp;Shivani Agarwal,&nbsp;Mitasha Singh,&nbsp;Manjula Jain,&nbsp;R K Chandoke,&nbsp;Kanika Singh,&nbsp;Dipti Sidam,&nbsp;Varsha Chauhan,&nbsp;Aparna Singh,&nbsp;Khushbu Katarya","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 is a systemic viral infection with a significant impact on the hematopoietic system, hemostasis as well as immune system. It would be of utmost importance to explore if the most routinely used tests could serve as an aid in determining patient's clinical status or predicting severity of the disease.</p><p><strong>Methods: </strong>A prospective cross-sectional study was conducted on 506 Covid-19 positive patients and 200 controls over a period of two months (June and July 2020). The cases were sub-classified based on disease severity into mild to moderate (n=337), severe (n=118) and very severe (n=51) and based on survivor status into survivors (n=473) and non-survivors (n=33).</p><p><strong>Results: </strong>There were statistically significant differences in WBC count, Absolute neutrophil count (ANC), Absolute lymphocyte count (ALC), absolute monocyte count (AMC), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR) Red blood cell distribution width (RDW-SD) and RDW CV between covid cases vs controls; among the clinical subgroups and among the survivors and non-survivors. There was a significant strong positive correlation between various parameters, that is, NLR and MLR (r: 0.852, P=0), MPV and PDW (r: 0.912, P=0), MPV and PLCR (r: 0.956, P=0), PDW and PLCR (r: 0.893, P=0). NLR (AUC: 0.676, P=0) was the best single parameter and NLR+RDW-CV was best combination parameter as per area under curve (0.871) of ROC to distinguish severe from mild to moderate disease.</p><p><strong>Conclusions: </strong>Leucocytosis, neutrophilia, lymphopenia and monocytosis were characteristic findings in covid cases while NLR and NLR+RDW-CV emerged as the most effective single and combination CBC parameters in distinguishing mild to moderate and severe cases respectively.</p>","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 2","pages":"180-190"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165721/pdf/ajbr0011-0180.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38986754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous methotrexate-related T-cell lymphoproliferative disorder with CD4, CD30, CD56, EBV-positive tumor cell infiltration: a case illustration and a brief review.","authors":"Issei Omori,&nbsp;Ruriko Kawanabe,&nbsp;Yuki Hashimoto,&nbsp;Aya Mitsui,&nbsp;Kako Kodama,&nbsp;Shinichi Nogi,&nbsp;Hirotaka Tsuno,&nbsp;Ayako Horita,&nbsp;Ikuo Saito,&nbsp;Hanako Ohmatsu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Methotrexate (MTX) is a commonly used anti-metabolite agent. Long-term MTX treatment can cause MTX-related lymphoproliferative disorder (MTX-LPD). T-cell LPDs comprise a small fraction of MTX-LPDs. Epstein-Barr virus (EBV)⁺ tumor cells are rarely detected in MTX-related T-cell LPDs (MTX T-LPDs). Therefore, there have been very few reports of EBV⁺ MTX T-LPD. We encountered a case of cutaneous MTX T-LPD with a unique cellular phenotype. The patient was a 71-year-old Japanese man with rheumatoid arthritis treated with MTX for 6 years. He was referred to our department with a 6-month history of red plaques and ulcerated lesions in both lower legs and a 2-week history of high fever and fatigue. Cutaneous specimens showed that medium-sized atypical lymphocytes were positive for CD3, CD4, CD30, CD56, and in situ hybridization for EBV-encoded RNA. The patient was diagnosed with cutaneous MTX T-LPD. Four months after discontinuation of MTX, the skin lesions had disappeared. This is the first report of cutaneous MTX T-LPD with CD4⁺CD30⁺CD56⁺EBV⁺ tumor cells.</p>","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 2","pages":"163-167"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165712/pdf/ajbr0011-0163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38986751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First reported case of secondary mixed phenotype acute leukemia after multiple myeloma.","authors":"Francesca Bacchiarri,&nbsp;Vincenzo Sammartano,&nbsp;Adele Santoni,&nbsp;Donatella Raspadori,&nbsp;Elisabetta Zappone,&nbsp;Marzia Defina,&nbsp;Sara Ciofini,&nbsp;Anna Sicuranza,&nbsp;Monica Bocchia,&nbsp;Alessandro Gozzetti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In recent years the outcome of patients with multiple myeloma (MM) has significantly improved, due to new drugs. However, some agents, i.e. the alkylating drug melphalan, can be associated with an increased incidence of secondary malignancies. Myelodysplastic syndromes and acute myeloid leukemia are reported in the literature, and rarely acute lymphoblastic leukemia. Here we describe a unique case of a 56-years old female patient affected by MM since 2015 in complete remission after autologous stem cell transplant and in lenalidomide maintenance, who developed 2 years later mixed phenotype acute leukemia (MPAL). The patient, refractory to both lymphoblastic and myeloid acute leukemia regimens, achieved complete remission with bi-specific anti-CD19/anti-CD3 monoclonal antibody blinatumomab and with hypomethylating agent azacytidine plus the BCL-2 inhibitor venetoclax. She then underwent hematopoietic stem cell transplantation from HLA-identical sibling donor and she is still in complete remission after 9 months. To the best of our knowledge, there are no cases in the literature describing MPAL after autologous transplant for MM. Our patient was treated with blinatumomab and venetoclax and achieved complete remission 9 months from allogeneic transplant. The mechanism underlying the development of MPAL is not completely understood and therapies are still lacking. In this context the combination of blinatumomab, azacytidine and venetoclax successfully used in this patient may provide food for thought for further studies in this rare setting of patients.</p>","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 1","pages":"123-131"},"PeriodicalIF":0.0,"publicationDate":"2021-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010609/pdf/ajbr0011-0123.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25540419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sea-blue histiocytosis in a patient with acute myeloid leukemia with myelodysplasia-related changes harboring isolated trisomy 9: pathognomonic or a coincidence?","authors":"Masahiro Manabe,&nbsp;Yuuji Hagiwara,&nbsp;Reiko Asada,&nbsp;Tomomi Wada,&nbsp;Keiji Shimizu,&nbsp;Yasuyoshi Sugano,&nbsp;Ki-Ryang Koh","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Although isolated trisomy 9, a form of chromosome aneuploidy, is rare in acute myeloid leukemia (AML), up to 30 cases of AML involving isolated trisomy 9 have been reported to date. We report the case of a 77-year-old female with AML, in which trisomy 9 was detected as an isolated aberration. In addition, the patient's bone marrow displayed so-called sea-blue histiocytosis. The accumulation of further cases of isolated trisomy 9-harboring AML involving sea-blue histiocytosis is necessary to determine whether the coexistence of these findings is pathognomonic or a coincidence.</p>","PeriodicalId":7479,"journal":{"name":"American journal of blood research","volume":"11 1","pages":"66-71"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010599/pdf/ajbr0011-0066.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25551641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}